TY - CHAP PY - 2004 DA - 2004// BT - Bone Health and Osteoporosis: A Report of the Surgeon General PB - U.S. Department of Health and Human Services, Office of the Surgeon General CY - Rockville, MD ID - ref1 ER - TY - STD TI - Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000, 17: 1-45. ID - ref2 ER - TY - JOUR AU - Riggs, B. L. AU - Melton, L. J. PY - 1995 DA - 1995// TI - The worldwide problem of osteoporosis: insights afforded by epidemiology JO - Bone VL - 17 UR - https://doi.org/10.1016/8756-3282(95)00258-4 DO - 10.1016/8756-3282(95)00258-4 ID - Riggs1995 ER - TY - JOUR AU - Ettinger, B. AU - Black, D. M. AU - Mitlak, B. H. AU - Knickerbocker, R. K. AU - Nickelsen, T. AU - Genant, H. K. AU - Christiansen, C. AU - Delmas, P. D. AU - Zanchetta, J. R. AU - Stakkestad, J. AU - Gluer, C. C. AU - Krueger, K. AU - Cohen, F. J. AU - Eckert, S. AU - Ensrud, K. E. AU - Avioli, L. V. AU - Lips, P. AU - Cummings, S. R. PY - 1999 DA - 1999// TI - Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JO - JAMA VL - 282 UR - https://doi.org/10.1001/jama.282.7.637 DO - 10.1001/jama.282.7.637 ID - Ettinger1999 ER - TY - JOUR AU - Delmas, P. D. AU - Ensrud, K. E. AU - Adachi, J. D. AU - Harper, K. D. AU - Sarkar, S. AU - Gennari, C. AU - Reginster, J. AU - Pols, H. A. AU - Recker, R. R. AU - Harris, S. T. AU - Wu, W. e. n. t. a. o. AU - Genant, H. K. AU - Black, D. M. AU - Eastell, R. PY - 2002 DA - 2002// TI - Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial JO - J Clin Endocrinol Metab VL - 87 UR - https://doi.org/10.1210/jcem.87.8.8750 DO - 10.1210/jcem.87.8.8750 ID - Delmas2002 ER - TY - JOUR AU - Sambrook, P. N. AU - Geusens, P. AU - Ribot, C. AU - Solimano, J. A. AU - Ferrer-Barriendos, J. AU - Gaines, K. AU - Verbruggen, N. AU - Melton, M. E. PY - 2004 DA - 2004// TI - Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX® versus EVISTA®Comparison Trial) International JO - J Intern Med VL - 255 UR - https://doi.org/10.1111/j.1365-2796.2004.01317.x DO - 10.1111/j.1365-2796.2004.01317.x ID - Sambrook2004 ER - TY - JOUR AU - Harris, S. T. AU - Watts, N. B. AU - Genant, H. K. AU - McKeever, C. D. AU - Hangartner, T. AU - Keller, M. AU - Chesnut, C. H. AU - Brown, J. AU - Eriksen, E. F. AU - Hoseyni, M. S. AU - Axelrod, D. W. AU - Miller, P. D. PY - 1999 DA - 1999// TI - Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial JO - JAMA VL - 282 UR - https://doi.org/10.1001/jama.282.14.1344 DO - 10.1001/jama.282.14.1344 ID - Harris1999 ER - TY - JOUR AU - Lufkin, E. G. AU - Wong, M. AU - Deal, C. PY - 2001 DA - 2001// TI - The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis JO - Rheum Dis Clin North Am VL - 27 UR - https://doi.org/10.1016/S0889-857X(05)70192-7 DO - 10.1016/S0889-857X(05)70192-7 ID - Lufkin2001 ER - TY - JOUR AU - Martino, S. AU - Cauley, J. A. AU - Barrett-Connor, E. AU - Powles, T. J. AU - Mershon, J. AU - Disch, D. AU - Secrest, R. J. AU - Cummings, S. R. PY - 2004 DA - 2004// TI - Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene JO - J Natl Cancer Inst VL - 96 UR - https://doi.org/10.1093/jnci/djh319 DO - 10.1093/jnci/djh319 ID - Martino2004 ER - TY - JOUR AU - Martino, S. AU - Disch, D. AU - Dowsett, S. A. AU - Keech, C. A. AU - Mershon, J. L. PY - 2005 DA - 2005// TI - Safety assessment of raloxifene over eight years in a clinical trial setting JO - Curr Med Res Opin VL - 21 UR - https://doi.org/10.1185/030079905X61839 DO - 10.1185/030079905X61839 ID - Martino2005 ER - TY - JOUR AU - Vogel, V. G. AU - Costantino, J. P. AU - Wickerham, D. L. AU - Cronin, W. M. AU - Cecchini, R. S. AU - Atkins, J. N. AU - Bevers, T. B. AU - Fehrenbacher, L. AU - Pajon, E. R. AU - Wade, J. L. AU - Robidoux, A. AU - Margolese, R. G. AU - James, J. AU - Lippman, S. M. AU - Runowicz, C. D. AU - Ganz, P. A. AU - Reis, S. E. AU - McCaskill-Stevens, W. AU - Ford, L. G. AU - Jordan, C. AU - Wolmark, N. PY - 2006 DA - 2006// TI - Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JO - JAMA VL - 295 UR - https://doi.org/10.1001/jama.295.23.joc60074 DO - 10.1001/jama.295.23.joc60074 ID - Vogel2006 ER - TY - JOUR AU - Barrett-Connor, E. AU - Mosca, L. AU - Collins, P. AU - Geiger, M. J. AU - Grady, D. AU - Kornitzer, M. AU - McNabb, M. A. AU - Wenger, N. K. PY - 2006 DA - 2006// TI - Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa062462 DO - 10.1056/NEJMoa062462 ID - Barrett-Connor2006 ER - TY - STD TI - Raloxifene (Evista) product label. 2007, Eli Lilly and Company, Indianapolis ID - ref13 ER - TY - JOUR AU - Kleerekoper, M. AU - Schein, J. R. PY - 2001 DA - 2001// TI - Comparative safety of bone remodeling agents with a focus on osteoporosis therapy JO - J Clin Pharmacol VL - 41 UR - https://doi.org/10.1177/00912700122010050 DO - 10.1177/00912700122010050 ID - Kleerekoper2001 ER - TY - JOUR AU - Bamias, A. AU - Kastritis, E. AU - Bamia, C. AU - Moulopoulos, L. A. AU - Melakopoulos, I. AU - Bozas, G. AU - Koutsoukou, V. AU - Gika, D. AU - Anagnostopoulos, A. AU - Papadimitriou, C. AU - Terpos, E. AU - Dimopoulos, M. A. PY - 2005 DA - 2005// TI - Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors JO - J Clin Onco VL - 23 UR - https://doi.org/10.1200/JCO.2005.02.8670 DO - 10.1200/JCO.2005.02.8670 ID - Bamias2005 ER - TY - STD TI - Ibandronate (Boniva) product label. 2005, Roche GlaxoSmithKlein, Nutley, NJ ID - ref16 ER - TY - STD TI - Alendronate (Fosamax) product label. 2005, Merck & Co, Inc., Whitehouse Station, NJ ID - ref17 ER - TY - STD TI - Risedronate (Actonel) product label. 2005, Proctor & Gamble Pharmaceuticals, Cincinnati, OH 45202 ID - ref18 ER - TY - STD TI - HEDIS Guidelines. Accessed August 9, 2005., [http://www.ncqa.org] UR - http://www.ncqa.org ID - ref19 ER - TY - JOUR AU - Deyo, R. A. AU - Cherkin, D. C. AU - Ciol, M. A. PY - 1992 DA - 1992// TI - Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases JO - J Clin Epidemiol VL - 45 UR - https://doi.org/10.1016/0895-4356(92)90133-8 DO - 10.1016/0895-4356(92)90133-8 ID - Deyo1992 ER - TY - JOUR AU - Cadarette, S. M. AU - Katz, J. N. AU - Brookhart, A. AU - Sturmer, T. AU - Stedman, M. R. AU - Solomon, D. H. PY - 2008 DA - 2008// TI - Relative effectiveness of osteoporosis drugs for preventing nonvertebral fractures JO - Ann Intern Med VL - 148 UR - https://doi.org/10.7326/0003-4819-148-9-200805060-00003 DO - 10.7326/0003-4819-148-9-200805060-00003 ID - Cadarette2008 ER - TY - JOUR AU - Birnbaum, H. G. AU - Cremieux, P. Y. AU - Greenberg, P. G. AU - LeLorier, J. AU - Ostrander, J. AU - Venditti, L. PY - 1999 DA - 1999// TI - Using healthcare claims data for outcomes research and pharmacoeconomic analysis JO - Pharmacoeconomics VL - 16 UR - https://doi.org/10.2165/00019053-199916010-00001 DO - 10.2165/00019053-199916010-00001 ID - Birnbaum1999 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6874/8/24/prepub UR - http://www.biomedcentral.com/1472-6874/8/24/prepub ID - ref23 ER -